TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22030100

Group type: EXPERIMENTAL
Intervention: Dynamic sound cue (following the trajectory of an object)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Static sound cue (sound remained stationary)
Number of subjects: 100
Study: 20705788

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine infusion (IV dexmedetomidine 2 μg · kg(‐1) over 10 minutes, followed by 0.7 μg · kg(‐1) · h(‐1))
Number of subjects: 122

Group type: COMPARATOR
Intervention: Fentanyl bolus (IV fentanyl 1 μg · kg(‐1))
Number of subjects: 122
Study: 18787524

Group type: EXPERIMENTAL
Intervention: Increased drinking water intake
Number of subjects: 173
Study: 15847998

Group type: EXPERIMENTAL
Intervention: 20 mg piroxicam freeze-dried tablet (Proxalyoc, Cephalon)
Number of subjects: 16

Group type: COMPARATOR
Intervention: 20 mg piroxicam capsule (Feldene, Pfizer)
Number of subjects: 16
Study: 12655322

Group type: EXPERIMENTAL
Intervention: Naltrexone (titrated to 50 mg/day)
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: Nalmefene (titrated to 40 mg/day)
Number of subjects: 215

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 215
Study: 10914864

Group type: EXPERIMENTAL
Intervention: Calcitriol (0.5 microg) and 1200 mg calcium daily
Number of subjects: 81

Group type: COMPARATOR
Intervention: Calcium and placebo calcitriol
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo calcitriol and placebo calcium
Number of subjects: 81
Study: 8985030

Group type: EXPERIMENTAL
Intervention: Short course radiotherapy (20 Gy in 1 week, daily dose 4 Gy)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard treatment (30 Gy in 3 weeks, daily dose 2 Gy)
Number of subjects: 100
Study: 1569224

Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine digluconate (CHX) used in oral irrigator, 2 x daily for 56 days
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo used in oral irrigator
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine digluconate (CHX)
Number of subjects: 16
Study: 6141188

Group type: EXPERIMENTAL
Intervention: Flurazepam, 30 mg
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Triazolam, 0.5 mg
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 31411498

Group type: EXPERIMENTAL
Intervention: Gla‐300
Number of subjects: 18
Study: 29784145

Group type: EXPERIMENTAL
Intervention: Thyme honey rinses
Number of subjects: 72

Group type: COMPARATOR
Intervention: Saline rinses
Number of subjects: 72
Study: 27043915

Group type: EXPERIMENTAL
Intervention: 1,100 ppm F as NaF
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 1,100 ppm F as SnF2
Number of subjects: 21

Group type: COMPARATOR
Intervention: 0 ppm F (fluoride-free)
Number of subjects: 21
Study: 24361804

Group type: EXPERIMENTAL
Intervention: Weight loss >2 kg
Number of subjects: 994

Group type: EXPERIMENTAL
Intervention: Weight loss >2 kg in LBBB patients
Number of subjects: 994
Study: 21543662

Group type: EXPERIMENTAL
Intervention: Atomoxetine (10, 40, 90, or 120 mg single dose; 40 or 60 mg twice a day for 7 days)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: CYP2D6*10/*10 genotype
Number of subjects: 49
Study: 21125038

Group type: EXPERIMENTAL
Intervention: Revascularisation plus medical therapy
Number of subjects: 806

Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 806
Study: 18042520

Group type: EXPERIMENTAL
Intervention: Increased intakes of fruits and stir-fried vegetables (3 servings of stir-fried vegetables and 2 servings of fresh fruits) for 4 weeks
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 34
Study: 15696181

Group type: EXPERIMENTAL
Intervention: Pilocarpine hydrochloride 5 mg tablet
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 12225311

Group type: EXPERIMENTAL
Intervention: Topiramate 200 mg/day
Number of subjects: 263

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 263
Study: 10730603

Group type: EXPERIMENTAL
Intervention: Computer reminder system (CaseWalker)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Manual reminder system (paper checklist)
Number of subjects: 78
Study: 9201655

Group type: EXPERIMENTAL
Intervention: Intravenous gammaglobulin (1 gm/kg, max 1 litre of 6 gm/100 ml in 10% w/v maltose solution)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Dummy solution (10% w/v maltose solution with 1% albumin of equivalent volume)
Number of subjects: 71
Study: 1332529

Group type: EXPERIMENTAL
Intervention: S(+)‐ketamine (1 mg/kg BW)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Racemic ketamine (2 mg/kg BW)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Both S(+)‐ketamine and racemic ketamine
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: S(+)‐ketamine
Number of subjects: 10
Study: 3510642

Group type: EXPERIMENTAL
Intervention: Intravenous pirmenol (50‐100 mg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 31382569

Group type: EXPERIMENTAL
Intervention: Educational intervention
Number of subjects: 1118

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1118
Study: 29404796

Group type: EXPERIMENTAL
Intervention: CRRT with a PMMA membrane hemofilter (PMMA group)
Number of subjects: 26

Group type: COMPARATOR
Intervention: CRRT with a polysulfone membrane hemofilter (PS group)
Number of subjects: 26

Group type: COMPARATOR
Intervention: NHD group
Number of subjects: 26
Study: 26410665

Group type: EXPERIMENTAL
Intervention: Self-rating level of perceived exertion during a 12-week cardiac rehabilitation programme.
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Self-rating level of perceived exertion with adjustment for rate-reducing medication.
Number of subjects: 97
Study: 23679091

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (NaHCO3) 0.3 g/kg body mass
Number of subjects: 7

Group type: COMPARATOR
Intervention: Sodium chloride (NaCl) 0.045 g/kg body mass
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 7
Study: 22500572

Group type: EXPERIMENTAL
Intervention: Bipolar tissue sealant device plus unipolar cautery
Number of subjects: 60

Group type: COMPARATOR
Intervention: Unipolar cautery alone
Number of subjects: 60
Study: 21526568

Group type: EXPERIMENTAL
Intervention: Ivabradine for 12 weeks
Number of subjects: 1777

Group type: EXPERIMENTAL
Intervention: Ivabradine group
Number of subjects: 1777

Group type: COMPARATOR
Intervention: Usual care group
Number of subjects: 1777
Study: 18622963

Group type: EXPERIMENTAL
Intervention: Iontophoretically induced acetylcholine vasodilation (IAV) measured with laser Doppler flux method (LDF)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Flow mediated dilation (FMD)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: LDF-measured EA
Number of subjects: 120
Study: 15886286

Group type: EXPERIMENTAL
Intervention: Nitroglycerin (NIT) at a starting dose of 10 microg/min
Number of subjects: 37

Group type: COMPARATOR
Intervention: Nitroprusside (NIP) at a starting dose of 0.25 microg/kg/min
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Both NIT and NIP
Number of subjects: 37
Study: 11840436

Group type: EXPERIMENTAL
Intervention: COBRA therapy (combination of prednisolone, methotrexate, and sulfasalazine)
Number of subjects: 0

Group type: COMPARATOR
Intervention: SSZ monotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: COBRA therapy
Number of subjects: 0
Study: 10636578

Group type: EXPERIMENTAL
Intervention: Full bladder (pre-filled to 60% of maximum capacity)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Empty bladder
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Full bladder
Number of subjects: 12
Study: 7792703

Group type: EXPERIMENTAL
Intervention: No-touch technique protocol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Surgery without the no-touch technique protocol
Number of subjects: 0
Study: 2039637

Group type: EXPERIMENTAL
Intervention: Methadone
Number of subjects: 40

Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 40
Study: 31609059

Group type: EXPERIMENTAL
Intervention: Major depressive disorder (MDD)‐related genetic risk score (GRSMDD)
Number of subjects: 251125

Group type: EXPERIMENTAL
Intervention: Carrying 10 additional BMI increasing alleles among depressed individuals
Number of subjects: 251125

Group type: COMPARATOR
Intervention: Carrying 10 additional BMI increasing alleles among controls
Number of subjects: 251125

Group type: EXPERIMENTAL
Intervention: Interaction with genetic risk score for BMI (GRSBMI)
Number of subjects: 251125
Study: 29083444

Group type: EXPERIMENTAL
Intervention: Identification of determinants in Aircraft aging (structural aging)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Development of P4 Systems medicine inspired new methodologies in predictive maintenance
Number of subjects: 0
Study: 26182172

Group type: EXPERIMENTAL
Intervention: Obesity grade 2 plus 3 (BMI >35.0)
Number of subjects: 67142

Group type: EXPERIMENTAL
Intervention: BMI of 35.0 or higher
Number of subjects: 67142

Group type: EXPERIMENTAL
Intervention: Obesity grade 2 plus 3
Number of subjects: 67142

Group type: EXPERIMENTAL
Intervention: Baseline BMI <25.0 with >5% body weight gain
Number of subjects: 67142

Group type: EXPERIMENTAL
Intervention: Weight change (gain or loss) among overweight or obese women
Number of subjects: 67142
Study: 23636283

Group type: EXPERIMENTAL
Intervention: Sodium intake > 1200 mg/day
Number of subjects: 331

Group type: EXPERIMENTAL
Intervention: Waist-to-height ratio > 0.5
Number of subjects: 331

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 331
Study: 21324118

Group type: EXPERIMENTAL
Intervention: Automatic electrical therapy for atrial tachycardia and fibrillation (AT/AF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional treatment of AT/AF (hospitalization for symptoms and in-hospital treatment)
Number of subjects: 0
Study: 19689798

Group type: EXPERIMENTAL
Intervention: cis-9, trans-11 CLA
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: trans-10,cis-12 CLA
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: 1:1 mixture of both isomers
Number of subjects: 34

Group type: COMPARATOR
Intervention: Reference linoleic acid oil preparation
Number of subjects: 34
Study: 17239165

Group type: EXPERIMENTAL
Intervention: 300 mg clopidogrel loading dose + 325 mg ASA
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 600 mg clopidogrel loading dose + 325 mg ASA
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 10 platelet concentrate units (equivalent to 40% V-PRP)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 12.5 units (50% V-PRP)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 2.5 units
Number of subjects: 11
Study: 15006921

Group type: EXPERIMENTAL
Intervention: IGF-1 highest tertile
Number of subjects: 493

Group type: EXPERIMENTAL
Intervention: IGFBP-3 highest tertile
Number of subjects: 493

Group type: EXPERIMENTAL
Intervention: IGF-1:IGFBP-3 molar ratio highest tertile
Number of subjects: 493
Study: 11521985

Group type: EXPERIMENTAL
Intervention: L-NAME 180 microg/kg/h
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Intraduodenal lipid infusion (2 kcal/min)
Number of subjects: 8

Group type: COMPARATOR
Intervention: 0.9% saline (control)
Number of subjects: 8
Study: 9972119

Group type: EXPERIMENTAL
Intervention: 20 mg doxycycline BID (Periostat)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Mechanical scaling and root planing (SRP)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Culture analysis of the 3 most prevalent isolates
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Etest susceptibility patterns
Number of subjects: 38
Study: 7804295

Group type: EXPERIMENTAL
Intervention: Structured baseline intervention including clear expectations, social reinforcement, and decelerative procedures.
Number of subjects: 1

Group type: COMPARATOR
Intervention: Natural baseline with staff reluctance to deliver instructions and corrective feedback.
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Reintroduction of regular staff with instruction and corrective feedback.
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Replication of both baseline conditions six months later.
Number of subjects: 1
Study: 3290018

Group type: EXPERIMENTAL
Intervention: sorbinil (aldose reductase inhibitor)
Number of subjects: 39

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 39
Study: 30760195

Group type: EXPERIMENTAL
Intervention: ω-3 fatty acids
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: nano-curcumin
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Combination of ω-3 fatty acids and nano-curcumin
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study: 28187335

Group type: EXPERIMENTAL
Intervention: Antipsychotic dose reduction
Number of subjects: 16
Study: 26711204

Group type: EXPERIMENTAL
Intervention: PCIA with dexmedetomidine and sufentanil (Group D)
Number of subjects: 152

Group type: COMPARATOR
Intervention: PCIA with sufentanil (Group S)
Number of subjects: 152
Study: 23896681

Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART) treatment
Number of subjects: 1434

Group type: COMPARATOR
Intervention: HIV replication (untreated state)
Number of subjects: 1434
Study: 21966218

Group type: EXPERIMENTAL
Intervention: Dietary Education plus Resistance Training (DERT)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Dietary Education (DE)
Number of subjects: 27
Study: 18253118

Group type: EXPERIMENTAL
Intervention: Irinotecan 60 mg m(‐2) on days 1 and 8 and cisplatin 60 mg m(‐2) on day 1 with etoposide 50 mg m(‐2) on days 1‐3 (n=55)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Irinotecan 60 mg m(‐2) on days 1 and 8 and cisplatin 60 mg m(‐2) on day 1 without etoposide (n=54)
Number of subjects: 109
Study: 16523797

Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 14561117

Group type: EXPERIMENTAL
Intervention: Alcohol group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 0
Study: 11206019

Group type: EXPERIMENTAL
Intervention: 40 mg of enoxaparin
Number of subjects: 1102

Group type: EXPERIMENTAL
Intervention: 20 mg of enoxaparin
Number of subjects: 1102

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1102
Study: 8969334

Group type: EXPERIMENTAL
Intervention: Intensive management
Number of subjects: 0
Study: 1467096

Group type: EXPERIMENTAL
Intervention: i.m. morphine 0.15 mg kg‐1 as required
Number of subjects: 40

Group type: COMPARATOR
Intervention: Patient-controlled analgesia (PCA) with i.v. morphine 1 mg and a 5-min lock out time
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study: 6372988

Group type: EXPERIMENTAL
Intervention: Splenectomy
Number of subjects: 189

Group type: COMPARATOR
Intervention: Nonsplenectomy
Number of subjects: 189
Study: 30245169

Group type: EXPERIMENTAL
Intervention: Androgen suppression combined with elective nodal and dose-escalated radiation therapy (DE-EBRT)
Number of subjects: 398

Group type: EXPERIMENTAL
Intervention: Low-dose-rate prostate brachytherapy boost (LDR-PB)
Number of subjects: 398

Group type: COMPARATOR
Intervention: Standard arm with 12 months of androgen deprivation therapy and pelvic EBRT
Number of subjects: 398
Study: 27322002

Group type: EXPERIMENTAL
Intervention: Osmotic pump Adalat® XL 60 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Matrix-type Adalat® Eins 30 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Quality control dissolution methods
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Level II biorelevant media
Number of subjects: 0
Study: 24607075

Group type: EXPERIMENTAL
Intervention: Stress management program (progressive muscle relaxation combined with diaphragmatic breathing) for 8 weeks
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 44
Study: 22781352

Group type: EXPERIMENTAL
Intervention: Nucleoside analogue treatment
Number of subjects: 23

Group type: COMPARATOR
Intervention: Alpha interferon treatment
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Both treatments (Nucleoside analogue and Alpha interferon)
Number of subjects: 23
Study: 20053951

Group type: EXPERIMENTAL
Intervention: EMG‐BFB treatment
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (conventional therapy)
Number of subjects: 20
Study: 18725513

Group type: EXPERIMENTAL
Intervention: 0.625 mg/day of conjugated equine estrogen plus 2.5 mg/day of medroxyprogesterone acetate
Number of subjects: 16608

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16608
Study: 16209674

Group type: EXPERIMENTAL
Intervention: Alcohol (vodka, 50% alcohol, 1 mL/kg body weight with 500 mL of orange and cranberry juice)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (500 mL of orange and cranberry juice)
Number of subjects: 10
Study: 12645831

Group type: EXPERIMENTAL
Intervention: Oral gemifloxacin (320 mg once daily, 5 days)
Number of subjects: 274

Group type: COMPARATOR
Intervention: Sequential intravenous (i.v.) ceftriaxone (1 g once daily, maximum 3 days) followed by oral cefuroxime axetil (500 mg twice daily, maximum 7 days)
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: Oral gemifloxacin
Number of subjects: 274

Group type: COMPARATOR
Intervention: Sequential i.v. ceftriaxone/oral cefuroxime
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 274
Study: 10859284

Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal coronary angioplasty (PTCA)
Number of subjects: 4039

Group type: EXPERIMENTAL
Intervention: Coronary artery bypass graft surgery (CABG)
Number of subjects: 4039

Group type: COMPARATOR
Intervention: PTCA (randomized trial)
Number of subjects: 4039

Group type: COMPARATOR
Intervention: CABG (randomized trial)
Number of subjects: 4039

Group type: EXPERIMENTAL
Intervention: PTCA (registry)
Number of subjects: 4039

Group type: EXPERIMENTAL
Intervention: CABG (registry)
Number of subjects: 4039

Group type: EXPERIMENTAL
Intervention: PTCA and CABG (treated diabetics)
Number of subjects: 4039
Study: 8879372

Group type: EXPERIMENTAL
Intervention: Ondansetron 8 mg twice a day
Number of subjects: 111

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 111
Study: 1672001

Group type: EXPERIMENTAL
Intervention: Short-term hospital stay (about 1 week)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Long-term hospital stay (about 4 weeks)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Both groups (short-term and long-term)
Number of subjects: 61
Study: 6436523

Group type: EXPERIMENTAL
Intervention: Peptide-based, low osmolality elemental diet
Number of subjects: 12

Group type: COMPARATOR
Intervention: Polymeric diet
Number of subjects: 12
Study: 30844989

Group type: EXPERIMENTAL
Intervention: Ischemic Preconditioning (IPC) at 250 mm Hg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo at 10 mm Hg
Number of subjects: 10
Study: 28592620

Group type: EXPERIMENTAL
Intervention: Trebananib 10 mg/kg plus sorafenib 400 mg orally twice daily
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Trebananib 15 mg/kg plus sorafenib 400 mg orally twice daily
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sorafenib historical control
Number of subjects: 30
Study: 25689289

Group type: EXPERIMENTAL
Intervention: 0.05% BAC
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 0.08% BAC
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: All BAC conditions
Number of subjects: 24
Study: 23344124

Group type: EXPERIMENTAL
Intervention: Deep extubation
Number of subjects: 100

Group type: COMPARATOR
Intervention: Awake extubation
Number of subjects: 100
Study: 21943112

Group type: EXPERIMENTAL
Intervention: SNPs in the ADIPOR2 locus (rs10848554, rs11061937, rs1058322, rs16928751)
Number of subjects: 484

Group type: EXPERIMENTAL
Intervention: Homozygous for the rare minor alleles of rs11061946 and rs11061973
Number of subjects: 484

Group type: EXPERIMENTAL
Intervention: mRNA expression levels of ADIPOR2
Number of subjects: 484
Study: 19480732

Group type: EXPERIMENTAL
Intervention: Soya isoflavones (116 mg isoflavone equivalents/d: 68 mg daidzein, 12 mg genistein, 36 mg glycitin)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 16580393

Group type: EXPERIMENTAL
Intervention: Letrozole
Number of subjects: 46

Group type: COMPARATOR
Intervention: Clomiphene citrate (CC)
Number of subjects: 46
Study: 12616111

Group type: EXPERIMENTAL
Intervention: Medical treatment
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Antireflux surgery
Number of subjects: 101
Study: 11340682

Group type: EXPERIMENTAL
Intervention: Newborn CF screening by heel-prick immunoreactive trypsin (IRT) measurement
Number of subjects: 464586

Group type: COMPARATOR
Intervention: Diagnosis by clinical presentation (unscreened group)
Number of subjects: 464586
Study: 9093424

Group type: EXPERIMENTAL
Intervention: Halofantrine-primaquine
Number of subjects: 66

Group type: COMPARATOR
Intervention: Chloroquine-primaquine
Number of subjects: 66
Study: 8181192

Group type: EXPERIMENTAL
Intervention: Omeprazole (40 mg daily for 1 week)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 6
Study: 3318598

Group type: EXPERIMENTAL
Intervention: Vitamin C (500 mg 4 times a day for 3 days)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 31468664

Group type: EXPERIMENTAL
Intervention: Sitagliptin (100 mg)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 28991749

Group type: EXPERIMENTAL
Intervention: Proposed consensus gene selection criteria using Distributed GPU implementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional SVM-RFE
Number of subjects: 0

Group type: COMPARATOR
Intervention: t-test
Number of subjects: 0
Study: 26653329

Group type: EXPERIMENTAL
Intervention: iEat foods (foods with good appearance and greater softness)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Blender-processed foods
Number of subjects: 0
Study: 24714538

Group type: EXPERIMENTAL
Intervention: Hypertrophy-type resistance training (3 sets of 10 RM with 90 seconds rest)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Strength-type resistance training (7 sets of 3 RM with 3 minutes rest)
Number of subjects: 17
Study: 23929523

Group type: EXPERIMENTAL
Intervention: Progressive exercise training (n = 12)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control exercise with no resistance (n = 12)
Number of subjects: 24